SEC Form 4 · accession 0001209191-15-074168
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Melissa A. Ashlock
Officer — See Remarks
Period of report
Oct 1, 2015
Accepted (ET)
Oct 5, 2015 · 6:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $10.24 | Oct 1, 2015 | A | 30,000 | A | — | Oct 1, 2025 | Common Stock | 30,000 | 30,000 | D |
| Employee Stock Option (right to buy)F2 | $10.24 | Oct 1, 2015 | A | 12,976 | A | — | — | Common Stock | 12,976 | 12,976 | D |
Explanation of responses
- F1The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on November 1, 2015, such that this option will be fully exercisable on October 1, 2019.This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
- F2The shares subject to this option shall vest and become exercisable, if at all, in 28 equal monthly installments upon the achievement of certain performance goals, which must be achieved by October 1, 2017, or such option will be subject to immediate forfeiture. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
Remarks
SVP, Translational Medicine and Therapeutics